The ArteraAI Prostate Test is transforming the risk stratification landscape for treating prostate cancer. For lower-risk patients, the test results can guide patient suitability for active surveillance. For intermediate-risk patients, there’s a predictive test result to determine if ST-ADT is beneficial. For high-risk patients, there’s insights to guide abiraterone usage along with radiation therapy and LT-ADT. And for recurrent patients after prostatectomy, the test can help guide ADT use alongside salvage radiation.
Listen to Erin Doser and Allison Palladino from Urology of St. Louis discuss how the test has impacted their clinical practice, as well as how the test results have helped with their patient discussions and follow up.
Fill out the form below to view the recording…
